{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:04:56Z","timestamp":1772766296569,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Unfractionated heparin (UFH) is the most widely used anticoagulant during extracorporeal membrane oxygenation (ECMO). Optimal dosing of UFH for children undergoing ECMO is unknown, leading to suboptimal exposure. We aimed to develop a population pharmacokinetic (PK) model for UFH in children undergoing venoarterial (VA) ECMO, using anti-Xa activity, to improve the initial dosing regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A retrospective observational study (March 2015 to May 2021) using nonlinear, mixed-effect modeling software (Monolix) and Monte Carlo simulations to optimize the dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting:<\/jats:title>\n                    <jats:p>Single-center study in a PICU in Paris, France.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients:<\/jats:title>\n                    <jats:p>All children under 18 years old who needed VA-ECMO and received continuous UFH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>None.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results:<\/jats:title>\n                    <jats:p>We included 59 children and 1305 anti-Xa activity results, 13% of which were outside the limits of quantification. Median (range) initial UFH bolus and infusion rate were 50 international units\/kg (20\u2013100) and 20 international units\/kg\/hr (9\u201340), respectively. Among the 1305 anti-Xa activity results, 875 (67%) were in the therapeutic range (0.3\u20130.7 international units\/mL), whereas 263 (20%) and 167 (13%) were below and above the PK target, respectively. A one-compartment model with first-order elimination and time-varying clearance best fitted the data. Body weight according to allometric scale on clearance and volume of distribution was the selected covariate. Initial clearance was low and increased until steady state was reached after 16 hours. Simulations showed that initial bolus of 40 international units\/kg followed by continuous infusion of 25, 20, and 15 international units\/kg\/hr for patients under 10, between 10 and 15 and above 15\u2009kg, respectively, improved exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In children undergoing VA-ECMO, body weight, and time-varying clearance explained the variability for UFH between subjects. This model can be used to optimize initial UFH dosing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/pcc.0000000000003887","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T15:00:28Z","timestamp":1767106828000},"page":"244-252","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Unfractionated Heparin Dosing in Pediatric Venoarterial Extracorporeal Membrane Oxygenation: Single-Center Retrospective Study, 2015\u20132021"],"prefix":"10.1097","volume":"27","author":[{"given":"No\u00e9mie","family":"de Cacqueray","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, UMR 1343, Pharmacologie et \u00e9valuations des th\u00e9rapeutiques chez l\u2019enfant et la femme enceinte, Paris, France."},{"name":"Service de R\u00e9animation et Soins Intensifs Polyvalents P\u00e9diatriques\u2014SMUR p\u00e9diatrique, H\u00f4pital Necker Enfants malades, APHP Centre\u2014Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frantz","family":"Foissac","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, UMR 1343, Pharmacologie et \u00e9valuations des th\u00e9rapeutiques chez l\u2019enfant et la femme enceinte, Paris, France."},{"name":"Service de pharmacologie Clinique, H\u00f4pital Cochin, APHP Centre\u2014Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naim","family":"Bouazza","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, UMR 1343, Pharmacologie et \u00e9valuations des th\u00e9rapeutiques chez l\u2019enfant et la femme enceinte, Paris, France."},{"name":"Service de pharmacologie Clinique, H\u00f4pital Cochin, APHP Centre\u2014Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domitille","family":"Gontharet","sequence":"additional","affiliation":[{"name":"Service de R\u00e9animation et Soins Intensifs Polyvalents P\u00e9diatriques\u2014SMUR p\u00e9diatrique, H\u00f4pital Necker Enfants malades, APHP Centre\u2014Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Borgel","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, U1176, H\u00e9mostase, Inflammation et Thrombose, Le Kremlin-Bic\u00eatre, France."},{"name":"Service d\u2019H\u00e9matologie Biologique, H\u00f4pital Necker Enfants malades, APHP Centre\u2014Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaux","family":"Pontailler","sequence":"additional","affiliation":[{"name":"Service de chirurgie cardiaque p\u00e9diatrie, H\u00f4pital Necker-Enfants Malades-M3C, APHP Centre \u2013 Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Raisky","sequence":"additional","affiliation":[{"name":"Service de chirurgie cardiaque p\u00e9diatrie, H\u00f4pital Necker-Enfants Malades-M3C, APHP Centre \u2013 Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Renolleau","sequence":"additional","affiliation":[{"name":"Service de R\u00e9animation et Soins Intensifs Polyvalents P\u00e9diatriques\u2014SMUR p\u00e9diatrique, H\u00f4pital Necker Enfants malades, APHP Centre\u2014Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Grimaud","sequence":"additional","affiliation":[{"name":"Service de R\u00e9animation et Soins Intensifs Polyvalents P\u00e9diatriques\u2014SMUR p\u00e9diatrique, H\u00f4pital Necker Enfants malades, APHP Centre\u2014Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Marc","family":"Tr\u00e9luyer","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, UMR 1343, Pharmacologie et \u00e9valuations des th\u00e9rapeutiques chez l\u2019enfant et la femme enceinte, Paris, France."},{"name":"Service de pharmacologie Clinique, H\u00f4pital Cochin, APHP Centre\u2014Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Oualha","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, UMR 1343, Pharmacologie et \u00e9valuations des th\u00e9rapeutiques chez l\u2019enfant et la femme enceinte, Paris, France."},{"name":"Service de R\u00e9animation et Soins Intensifs Polyvalents P\u00e9diatriques\u2014SMUR p\u00e9diatrique, H\u00f4pital Necker Enfants malades, APHP Centre\u2014Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agathe","family":"B\u00e9ranger","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, UMR 1343, Pharmacologie et \u00e9valuations des th\u00e9rapeutiques chez l\u2019enfant et la femme enceinte, Paris, France."},{"name":"Service de R\u00e9animation et Soins Intensifs Polyvalents P\u00e9diatriques\u2014SMUR p\u00e9diatrique, H\u00f4pital Necker Enfants malades, APHP Centre\u2014Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"R1-20260305","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MAT.0000000000002128","article-title":"Extracorporeal Life Support Organization registry international report 2022: 100,000 survivors.","volume":"70","author":"Tonna","year":"2024","journal-title":"ASAIO J"},{"key":"R2-20260305","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MAT.0000000000001652","article-title":"2021 ELSO adult and pediatric anticoagulation guidelines.","volume":"68","author":"McMichael","year":"2022","journal-title":"ASAIO J"},{"issue":"7 Suppl 1","key":"R3-20260305","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1097\/PCC.0000000000003495","article-title":"Anticoagulant medications: The pediatric extracorporeal membrane oxygenation anticoagulation collaborative consensus conference.","volume":"25","author":"Cashen","year":"2024","journal-title":"Pediatr Crit Care Med"},{"key":"R4-20260305","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/PCC.0000000000003480","article-title":"The pediatric extracorporeal membrane oxygenation anticoagulation collaborativE (PEACE) consensus conference.","volume":"25","author":"Alexander","year":"2024","journal-title":"Pediatr Crit Care Med"},{"issue":"7 Suppl 1","key":"R5-20260305","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/PCC.0000000000003496","article-title":"The influence of the extracorporeal membrane oxygenation circuit and components on anticoagulation management: The pediatric extracorporeal membrane oxygenation anticoagulation collaborative consensus conference.","volume":"25","author":"Himebauch","year":"2024","journal-title":"Pediatr Crit Care Med"},{"issue":"7 Suppl 1","key":"R6-20260305","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1097\/PCC.0000000000003494","article-title":"Anticoagulation monitoring and targets: The pediatric extracorporeal membrane oxygenation anticoagulation collaborative consensus conference.","volume":"25","author":"Ozment","year":"2024","journal-title":"Pediatr Crit Care Med"},{"key":"R7-20260305","doi-asserted-by":"crossref","first-page":"988681","DOI":"10.3389\/fped.2022.988681","article-title":"Hemostasis in neonatal ECMO.","volume":"10","author":"Cortesi","year":"2022","journal-title":"Front Pediatr"},{"key":"R9-20260305","doi-asserted-by":"crossref","first-page":"e001512","DOI":"10.1136\/bmjpo-2022-001512","article-title":"Population pharmacokinetics in critically ill neonates and infants undergoing extracorporeal membrane oxygenation: A literature review.","volume":"6","author":"Yalcin","year":"2022","journal-title":"BMJ Paediatr Open"},{"key":"R10-20260305","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/PCC.0000000000002696","article-title":"Anticoagulation and transfusion management during neonatal and pediatric extracorporeal membrane oxygenation: A survey of medical directors in the United States.","volume":"22","author":"Ozment","year":"2021","journal-title":"Pediatr Crit Care Med"},{"key":"R11-20260305","first-page":"228","article-title":"Comparison of time within therapeutic range using anti-factor Xa versus activated partial thromboplastin time monitoring of unfractionated heparin in children.","volume":"28","author":"Haftmann","year":"2023","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R12-20260305","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics.","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R13-20260305","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/jcph.2333","article-title":"Pharmacokinetic modeling using real-world data to optimize unfractionated heparin dosing in pediatric patients on extracorporeal membrane oxygenation and evaluate target achievement-clinical outcomes relationship.","volume":"64","author":"Salem","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"R14-20260305","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/pharmaceutics16060770","article-title":"Heparin dosing regimen optimization in veno-arterial extracorporeal membrane oxygenation: A pharmacokinetic analysis.","volume":"16","author":"Lanoisel\u00e9e","year":"2024","journal-title":"Pharmaceutics"},{"key":"R15-20260305","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40262-020-00949-0","article-title":"The influence of haemostatic system maturation on the dose-response relationship of unfractionated heparin.","volume":"60","author":"Derbalah","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"R16-20260305","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11095-016-2033-y","article-title":"Clinical pharmacology studies in critically ill children.","volume":"34","author":"Thakkar","year":"2017","journal-title":"Pharm Res"},{"key":"R17-20260305","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/bcp.12930","article-title":"Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients.","volume":"82","author":"Al-Sallami","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"R18-20260305","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/jcph.2007","article-title":"Reassessing the pediatric dosing recommendations for unfractionated heparin using real-world data: A pharmacokinetic-pharmacodynamic modeling approach.","volume":"62","author":"Salem","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"R19-20260305","doi-asserted-by":"crossref","first-page":"e1034","DOI":"10.1097\/PCC.0000000000003776","article-title":"Hyperlactatemia in critically ill children: Modeling early recovery kinetics after initiation of extracorporeal membrane oxygenation.","volume":"26","author":"Au","year":"2025","journal-title":"Pediatr Crit Care Med"},{"key":"R20-20260305","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/PCC.0000000000003525","article-title":"Balancing pharmacologic anticoagulation in extracorporeal membrane oxygenation: Is it now time to follow the path less taken?","volume":"25","author":"Parker","year":"2024","journal-title":"Pediatr Crit Care Med"},{"issue":"7 Suppl 1","key":"R21-20260305","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1097\/PCC.0000000000003492","article-title":"Recommendations on monitoring and replacement of antithrombin, fibrinogen, and von Willebrand factor in pediatric patients on extracorporeal membrane oxygenation: The pediatric extracorporeal membrane oxygenation anticoagulation collaborative consensus conference.","volume":"25","author":"Zantek","year":"2024","journal-title":"Pediatr Crit Care Med"},{"issue":"7 Suppl 1","key":"R22-20260305","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1097\/PCC.0000000000003488","article-title":"Priorities for clinical research in pediatric extracorporeal membrane oxygenation anticoagulation from the pediatric extracorporeal membrane oxygenation anticoagulation collaborative consensus conference.","volume":"25","author":"Muszynski","year":"2024","journal-title":"Pediatr Crit Care Med"},{"key":"R23-20260305","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.thromres.2023.07.012","article-title":"Bivalirudin or heparin for systemic anticoagulation during pediatric extracorporeal membrane oxygenation: Multicenter retrospective study.","volume":"229","author":"Hamzah","year":"2023","journal-title":"Thromb Res"},{"key":"R24-20260305","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1097\/PCC.0000000000003527","article-title":"Bivalirudin monitoring in pediatric ventricular assist device and extracorporeal membrane oxygenation: Analysis of single-center retrospective cohort data 2018-2022.","volume":"25","author":"Engel","year":"2024","journal-title":"Pediatr Crit Care Med"},{"key":"R25-20260305","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1097\/PCC.0000000000003642","article-title":"Prospective randomized pilot study comparing bivalirudin versus heparin in neonatal and pediatric extracorporeal membrane oxygenation.","volume":"26","author":"McMichael","year":"2025","journal-title":"Pediatr Crit Care Med"},{"key":"R26-20260305","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1055\/s-0043-1770096","article-title":"Factors influencing anti-xa assays: A multicenter prospective study in critically ill and noncritically ill patients receiving unfractionated heparin.","volume":"123","author":"Lasne","year":"2023","journal-title":"Thromb Haemost"},{"key":"R27-20260305","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13054-021-03554-0","article-title":"Anti-Xa activity and hemorrhagic events under extracorporeal membrane oxygenation (ECMO): A multicenter cohort study.","volume":"25","author":"Descamps","year":"2021","journal-title":"Crit Care"},{"key":"R28-20260305","doi-asserted-by":"crossref","first-page":"e12687","DOI":"10.1002\/rth2.12687","article-title":"Coagulation in pediatric extracorporeal membrane oxygenation: A systematic review of studies shows lack of standardized reporting.","volume":"6","author":"Drop","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"R29-20260305","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1097\/PCC.0000000000003679","article-title":"Hemostatic outcome definitions in pediatric extracorporeal membrane oxygenation: Challenges in cohorts from Rotterdam (2019-2023) and Melbourne (2016-2022).","volume":"26","author":"Drop","year":"2025","journal-title":"Pediatr Crit Care Med"},{"key":"R30-20260305","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S2352-4642(24)00132-9","article-title":"Definitions of adverse events associated with extracorporeal membrane oxygenation in children: Results of an international Delphi process from the ECMO-CENTRAL ARC.","volume":"8","author":"Alexander","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"R31-20260305","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/PCC.0000000000003270","article-title":"Realizing potential: Pediatric extracorporeal membrane oxygenation needs common adverse event definitions to improve outcomes.","volume":"24","author":"Alexander","year":"2023","journal-title":"Pediatr Crit Care Med"},{"key":"R32-20260305","doi-asserted-by":"crossref","first-page":"100064","DOI":"10.1016\/j.bvth.2025.100064","article-title":"ECMO-induced coagulopathy: Strategic initiatives for research and clinical practice (a workshop report of the NHLBI).","volume":"2","author":"Levy","year":"2025","journal-title":"Blood Vessel Thromb Hemost"},{"issue":"7 Suppl 1","key":"R33-20260305","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1097\/PCC.0000000000003489","article-title":"Management of bleeding and thrombotic complications during pediatric extracorporeal membrane oxygenation: The pediatric extracorporeal membrane oxygenation anticoagulation collaborative consensus conference.","volume":"25","author":"Rintoul","year":"2024","journal-title":"Pediatr Crit Care Med"}],"container-title":["Pediatric Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PCC.0000000000003887","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:00:52Z","timestamp":1772722852000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PCC.0000000000003887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pcc.0000000000003887","relation":{},"ISSN":["1529-7535","1947-3893"],"issn-type":[{"value":"1529-7535","type":"print"},{"value":"1947-3893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]}}}